Switzerland | Imports and Exports | World | Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products | Value (US$) and Value Growth, YoY (%) | 2012 - 2023
| Commodity | Reporter | Partner | Trade flow | Indicator | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
| 3002. Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc | Switzerland | World | Exports | Value (US$) | 21,651,654,340.00 | 23,907,756,121.83 | 25,910,101,715.79 | 24,744,221,148.75 | 26,182,745,616.48 | 28,075,301,968.70 | 29,045,467,062.35 | 34,427,303,343.41 | 39,536,328,779.54 | 50,356,969,983.66 | 50,059,714,526.29 | 52,435,093,214.02 |
| Value Growth, YoY (%) | 6.77 | 10.41 | 8.37 | -4.49 | 5.81 | 7.22 | 3.45 | 18.52 | 14.84 | 27.36 | -0.59 | 4.74 | ||||
| Imports | Value (US$) | 5,238,567,180.00 | 6,237,441,882.29 | 7,165,955,518.62 | 7,106,236,676.15 | 7,425,691,315.81 | 8,805,899,437.68 | 9,946,995,088.81 | 9,931,779,861.30 | 12,395,870,396.73 | 14,522,502,515.36 | 16,210,816,363.59 | 17,677,256,557.65 | |||
| Value Growth, YoY (%) | -2.53 | 19.06 | 14.88 | -0.83 | 4.49 | 18.58 | 12.95 | -0.15 | 24.81 | 17.15 | 11.62 | 9.04 |
The value of exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" from Switzerland totalled $ 52 billion in 2023. Sales of commodity group 3002 from Switzerland went up by 4.74% compared to 2022: exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" went up by $ 2.37 billion (cumulative exports of commodity group 3002 from Switzerland amounted $50 billion in 2022)
Exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" amounted to 12.4% of total exports from Switzerland (cumulative merchandise exports from Switzerland totalled $ 420 billion in 2023). The share of commodity group 3002 in total exports from Switzerland decreased by 0.031 p.p. compared to 2022 (it was 12.5% in 2022 and cumulative exports from Switzerland were equal to $ 400 billion).
Exports of commodity group 3002 amounted to 52% of total sales of group "" from Switzerland in 2023 (the value of exports of commodity group from Switzerland amounted to $98 billion in 2023). The share of exports of commodity group 3002 in sales of commodity group from Switzerland increased by 1.9 p.p. compared to 2022 (it was 51% in 2022, and exports of commodity group from Switzerland were $98 billion).
Exports of commodity group 3002 amounted to 99 percent of total sales of group "" from Switzerland in 2023 (the value of exports of commodity group from Switzerland amounted to 52 billion USD in 2023). The share of exports of commodity group 3002 in sales of commodity group from Switzerland lowered by -0 p.p. compared to 2022 (it was 99 percent in 2022, and exports of commodity group from Switzerland amounted to 50 billion USD).
Where does Switzerland export Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc?
Top export destinations of "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" from Switzerland in 2023:
- USA with a share of 32% (17 billion US$)
- Germany with a share of 14.5% (7.65 billion US$)
- China with a share of 5.82% (3.05 billion US$)
- France with a share of 4.15% (2.18 billion US$)
- Japan with a share of 3.81% (2 billion US$)
- Canada with a share of 3.35% (1.76 billion US$)
- Belgium with a share of 3.32% (1.74 billion US$)
- United Kingdom with a share of 2.99% (1.57 billion US$)
- Italy with a share of 2.72% (1.42 billion US$)
- Spain with a share of 2.21% (1.16 billion US$)
Exports structure of 3002 - Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc - from Switzerland in 2023 represented by the following main commodity groups:
- 0.132% (69 million US$): 300290 - Human blood; animal blood prepared for therapeutic/prophylactic/diagnostic uses; toxins, cultures of micro-organisms (excl. yeasts) & sim. products
The value of imports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" to Switzerland totalled $ 17.6 billion in 2023. Sales of commodity group 3002 to Switzerland went up by 9.04% compared to 2022: imports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" went up by $ 1.46 billion (the value of imports of commodity group 3002 to Switzerland was equal to $16.2 billion in 2022)
Imports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" accounted for 4.85% of total import flow to Switzerland (in 2023, total imports to Switzerland amounted to $ 363 billion). The share of commodity group 3002 in total imports to Switzerland increased by 0.307 p.p. compared to 2022 (it was 4.55% in 2022 and cumulative imports to Switzerland were equal to $ 356 billion).
Imports of commodity group 3002 reached 30% of total imports of group "" to Switzerland in 2023 (imports of commodity group to Switzerland totalled $58 billion in 2023). The share of purchases of commodity group 3002 in imports of commodity group to Switzerland went down by 3.14 p.p. compared to 2022 (it was 33% in 2022, and imports of commodity group to Switzerland accounted for $48 billion).
Where does Switzerland import Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc from?
Top trading partners (import of "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc") of Switzerland in 2023:
- USA with a share of 22% (3.96 billion US$)
- Germany with a share of 21% (3.81 billion US$)
- Ireland with a share of 18% (3.19 billion US$)
- Korea with a share of 8.77% (1.55 billion US$)
- Japan with a share of 8.09% (1.43 billion US$)
- Singapore with a share of 4.37% (772 million US$)
- Italy with a share of 2.8% (495 million US$)
- Belgium with a share of 2.78% (492 million US$)
- Denmark with a share of 2.13% (377 million US$)
- France with a share of 2.07% (367 million US$)
Imports structure of 3002 - Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc - to Switzerland in 2023 represented by the following main commodity groups:
- 0.223% (39 million US$): 300290 - Human blood; animal blood prepared for therapeutic/prophylactic/diagnostic uses; toxins, cultures of micro-organisms (excl. yeasts) & sim. products
